Analyst Price Targets — RZLT
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| January 8, 2026 1:04 pm | — | Wedbush | $2.00 | $2.22 | TheFly | Rezolute price target raised to $2 from $1 at Wedbush |
| December 12, 2025 2:19 pm | Jason McCarthy | Maxim Group | $4.00 | $1.58 | TheFly | Rezolute price target lowered to $4 from $20 at Maxim |
| December 12, 2025 11:05 am | Douglas Tsao | H.C. Wainwright | $5.00 | $1.40 | TheFly | Rezolute price target lowered to $5 from $14 at H.C. Wainwright |
| December 11, 2025 8:32 pm | Albert Lowe | Craig-Hallum | $2.00 | $1.40 | TheFly | Rezolute downgraded to Hold from Buy at Craig-Hallum |
| December 11, 2025 5:30 pm | Julian Harrison | BTIG | $5.00 | $1.40 | TheFly | Rezolute price target lowered to $5 from $17 at BTIG |
| December 11, 2025 3:45 pm | — | Wedbush | $1.00 | $1.25 | TheFly | Wedbush downgrades Rezolute to Neutral after congenital hyperinsulinism miss |
| December 5, 2025 8:28 pm | — | Jefferies | $20.00 | $10.42 | TheFly | Rezolute price target raised to $20 from $15 at Jefferies |
| October 29, 2025 9:42 am | — | JMP Securities | $17.00 | $9.49 | TheFly | Rezolute price target raised to $17 from $9 at Citizens JMP |
| September 18, 2025 4:23 pm | — | Maxim Group | $20.00 | $8.20 | TheFly | Rezolute price target raised to $20 from $15 at Maxim |
| September 20, 2024 5:22 am | Julian Harrison | BTIG | $7.50 | $2.41 | StreetInsider | BTIG Reiterates Buy Rating on Rezolute (RZLT) |
Latest News for RZLT
RZLT stock jumps 12% after an FDA meeting highlights ersodetug data and next steps, despite an earlier phase III setback in the congenital HI study.
In a recent update, Rezolute shared insights from its March 17 meeting with the FDA regarding its Phase 3 sunRIZE trial for ersodetug, aimed at treating congenital hyperinsulinism.
REDWOOD CITY, Calif., March 24, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by all forms of hyperinsulinism (HI), today announced outcomes from an in-person Type B meeting with the U.S. Food and Drug Administration (FDA) held on March 17, 2026, related to sunRIZE, a Phase 3, multicenter, double-blind,…
ADMA Biologics (NASDAQ: ADMA - Get Free Report) and Rezolute (NASDAQ: RZLT - Get Free Report) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, profitability, dividends, valuation, analyst recommendations, risk and earnings. Profitability This table compares ADMA Biologics and Rezolute's net
NEW YORK--(BUSINESS WIRE)---- $RZLT #ClassAction--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Rezolute, Inc. (“Rezolute” or the “Company”) (NASDAQ: RZLT). Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for RZLT.
U.S. House Trading
No House trades found for RZLT.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.